Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.
-
Merck KGaA has agreed to acquire Bio-Techne (NasdaqGS:TECH) for $11.5b in an all cash deal.
-
Bio-Techne's board has unanimously approved the transaction, which is now subject to regulatory review.
-
The companies highlight expected synergies and accretion to Merck KGaA's earnings following completion.
For investors tracking Bio-Techne, the agreed $11.5b acquisition by Merck KGaA lands after a sharp move in the stock, with NasdaqGS:TECH up 22% over the past week and 47% over the past month. The current share price of $70.7 comes against a mixed longer term picture, including a 37.2% gain over the past year but declines over the past 3 and 5 years.
This deal puts a clear corporate event at the center of the Bio-Techne story, with regulatory review now the key hurdle to closing. Readers will likely focus on how the cash offer compares with recent trading levels, alongside what Merck KGaA intends to do with Bio-Techne's tools and diagnostics assets once the transaction is complete.
Stay updated on the most important news stories for Bio-Techne by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Bio-Techne.
We've flagged 1 risk for Bio-Techne. See which could impact your investment.
Quick Assessment
-
❌ Price vs Analyst Target: Bio-Techne trades at US$70.70, about 7.5% above the US$65.75 analyst price target and near the top of the US$50 to US$75 range.
-
❌ Simply Wall St Valuation: Shares are reported as trading 39.5% above estimated fair value, which flags a premium valuation.
-
✅ Recent Momentum: The stock is up 47.0% over 30 days, reflecting strong short term momentum into the Merck KGaA deal.
There's only one way to know the right time to buy, sell or hold Bio-Techne. Head to Simply Wall St's company report for the latest analysis of Bio-Techne's Fair Value .
Key Considerations
-
📊 With a signed US$11.5b all cash deal, the Bio-Techne thesis now centers on deal certainty, timing and any potential competing interest.
-
📊 Watch where the share price trades relative to the cash offer, any regulatory milestones, and updates to analyst targets or deal terms.
-
⚠️ There is 1 flagged risk, including large one off items affecting results, which could influence views on standalone valuation if the transaction changes or is delayed.
Dig Deeper
For the full picture including more risks and rewards, check out the complete Bio-Techne analysis . Alternatively, you can check out the community page for Bio-Techne to see how other investors believe this latest news will impact the company's narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include TECH .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
